At the time of clinical presentation, the very heterogeneous group of pediatric and adult gliomas carry a 11 wide range of diverse somatic genomic alterations. These include chromosome-sized gains and losses, 12 focal amplification and deletions, rearrangements resulting in transcript fusions, small 13 insertions/deletions, and point mutations. Tumor cells pay a penalty for maintaining these abnormalities 14 which therefore must provide cells with a competitive advantage to become engrained into the glioma 15 genome. Here, we propose a model for gliomagenesis consisting of five consecutive phases that glioma 16 cells have traversed prior to diagnosis. Tumor growth is repressed by activated DNA damage response 17 pathways and dysfunctional telomeres in physiological conditions. Disruption of the p16-RB-p53 18 pathway and the acquisition of a telomere maintenance mechanism can bypass these bottlenecks. We 19 relate somatic alterations to each of these steps, in order to reconstruct the life history of glioma.
: Model of the molecular life history of gliomas. The temporal sequence of events can be subdivided in five phases (I -V) represented in different colors. A. The number of dividing cells (or proliferation rate) across each phase. Proliferation peaks towards the end of growth phases and dips going into senescence phases. B. The tumor mass across each phase. Tumor mass increases exponentially during growth phases and logarithmically during senescence phases. C. Telomere length across each phase. Telomere length over time follows a pattern that is inverse to tumor mass. D. Cell doubling diagram indicating the growth barriers (senescence phases) and resulting selection bottleneck. E. Somatic alterations associated with different phases in gliomagenesis. The timing of each event is indicated on the x-axis of panel C. Genomic Instability events are accumulated during phase III-IV. Of note, this model is a simplified representation of true gliomagenesis. The x-axis is not drawn to scale, in part because the duration of the phases likely varies from cell to cell and between various tumor types. Furthermore, the position of the curves is arbitrary as cells in a tumor may not be in sync. BFB = breakage-fusion-bridge, DM = double minute, ALT = Alternative lengthening of telomeres
Introduction
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As with other human cancers, the pathogenesis and molecular evolution of glial tumors of the central 30 nervous system (CNS) is often characterized by chromosomal aberrations, widespread or focal copy 31 number changes and targeted gain and loss of function events in oncogenes and tumor suppressor 32 genes [1] [2] [3] . Various permutations of somatic alterations are associated with distinct tumor entities and 33 differential sensitivities to treatment, such as a chromosome 1p/19q-codeletion in oligodendrogliomas 34 conferring increased sensitivity to chemotherapy [4, 5] . In this review, we propose five phases in 35 gliomagenesis ( Figure 1 ) that occur sequentially and ultimately lead to the tumor at clinical diagnosis.
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Each phase is characterized by distinct molecular alterations and phenotypic characteristics, such as 37 differences in growth dynamics and evolutionary mechanisms. A critical assumption in our model is the 38 existence of two growth barriers, which we refer to as oncogene-induced and replicative senescence. 39 Similar barriers have been described in detail in the context of cultured epithelial cells and fibroblasts 40 and much of this work has paved the road for our understanding of these mechanisms in gliomagenesis 41 [6] [7] [8] . We systematically review the evidence for our model and propose candidate mechanisms where 42 definitive evidence is lacking. We discuss in depth our model across various entities of diffuse glioma Note that especially diffuse gliomas are nowadays classified based on integration of histologic and molecular characteristics. This review focusses on diffuse gliomas, and on pilocytic astrocytomas (the remaining glioma categories are shaded in yellow). Diffuse gliomas are graded as WHO grade II to IV (least to most malignant). Many non-diffuse gliomas are relatively indolent (WHO grade I), while the most malignant tumors in this category are graded as WHO grade III. For some rare and/or only recently identified neoplasms (esp. angiocentric glioma, diffuse leptomeningeal glioneuronal tumor) an unequivocal malignancy grade has not been assigned yet.
Classification of human gliomas 60
Gliomas encompass a very diverse group and account for the great majority of tumors originating in the 61 parenchyma of the CNS [9] . Traditionally, gliomas are classified according to their microscopic 62 similarities with (precursors of) glial cells and then designated as astrocytomas, oligodendrogliomas, 63 mixed gliomas (mainly oligoastrocytomas) or ependymomas. Two larger glioma groups are recognized: 
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For over a century, such microscopic evaluation has provided the gold standard for the diagnosis of 79 gliomas, assessment of prognosis and formed the basis for therapeutic management. However, multiple 80 studies showed that a purely histopathologic classification suffers from considerable inter-and 81 intraobserver variability [11] [12] [13] . In the course of the last two decades it became increasingly clear that 82 molecular characteristics may provide a more robust and objective basis for subtyping of diffuse 83 gliomas. 
A Model for the Temporal Molecular Pathogenesis of Gliomas
Phase I: Initial Growth
118
The theory that cancer results from accumulation of mutations over time, in a subset of patients 119 combined with contribution of inherited risk factors, has been around for over six decades and has been 120 refined over the years [31] [32] [33] [34] . For the purpose of this review we will consider a glioma initiating event 121 to be the first acquired (somatic) event towards developing glioma. This event should provide a 122 competitive growth advantage, either by directly increasing proliferation or by creating the conditions in 123 which increased proliferation may happen. Cells and their progeny characterized by such an event will 124 be primed to outcompete neighboring cells giving rise to an initial tumor mass. While germline events 125 that contribute to glioma risk may precede such glioma initiating events, their incomplete penetrance 126 suggests that they cannot be considered as causal for glioma formation and instead prime the 
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Combined this raises the possibility that these mutations may contribute to tumorigenesis via other 470 pathways than its effect on telomerase alone, providing a biological reason for these mutations to 471 contribute to gliomagenesis early in phase I and before the onset of dysfunctional telomeres. In a 472 glioma-specific analysis it was found that nearly all tumors with the 'phase I event' +7/-10 or 'phase II 
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Although roles for TERT outside of telomere maintenance remain to be definitively understood, these 488 observations provide a sound argument that TERT promoter mutations can occur early in or even before 489 gliomagenesis while providing a means towards immortalization at a later stage. [183] . The prevalence of ALT in IDH-wildtype diffuse gliomas is higher than the frequency of ATRX 500 mutations, suggesting that some of these tumors may use ATRX-independent mechanisms to activate 501 ALT [160] . In a similar fashion, the prevalence of telomerase activity is higher than the prevalence of 502 TERT promoter mutations in this tumor type, suggesting that these tumors may use TERT promoter 503 independent mechanisms for the reactivation of telomerase [182] . Several candidate mechanisms have 504 been previously described in glioma, including TERT promoter methylation or TERT amplifications [184] .
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Contrary to adult IDH-wildtype diffuse glioma, H3-mutant malignant pediatric glioma frequently 506 demonstrate ALT [185] , and several studies reported frequent co-occurrence of ATRX mutations in both 507 H3 K27 and G34 mutant gliomas. However, reports of co-occurrence vary between 30% and 60% for K27 508 and 75% to 100% for G34, suggesting that there is a role for telomerase in many of these tumors as well 509 [186] . 510 511 Figure 5. A. An integrated clonal evolution/cancer stem cell model for gliomagenesis assumes that sequential mutations and selection pressure drive the evolution of cancer stem-like cells. At the same time these stem-like cells may give rise to more differentiated (ie. phase IV) offspring that may divide further but rapidly become growth arrested. B. According to our model these cells may be senescent and contribute to the cancer phenotype by eliciting a micro-environment response via SASP. SASP = senescence-associated secretory phenotype; ILs = interleukines; CXCLs = chemokines (C-X-C motif); CCLs = chemokines (C-C motif)
Phase V: Immortalization & Dedifferentiation
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The glioma stem cell theory states that amongst all cancerous cells in a tumor, a subset of cells act as 
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These findings imply that senescent and differentiated phase IV cells may be crucial for shaping the 576 immune microenvironment in gliomas ( Figure 5B 
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The germline mutations underlying NF1/NF2 and Li-Fraumeni syndrome represent pathways that both 617 need to be disrupted for a malignant tumor to form. The fact that nearly all patients with NF1/NF2 618 develop one or more benign tumors can be understood by acknowledging that in these disorders a 619 germline tumor initiating event is involved. Unless this pathway is supplemented by a senescence 620 bypass event these tumors do not readily proceed to malignancy. In contrast, Li-Fraumeni syndrome is 621 characterized by an increased risk for malignant tumors in many (but not all) patients with this 622 syndrome. In this syndrome, the germline senescence bypass event needs to be supplemented by a 623 tumor initiating event for a tumor to develop, and such tumors may be more aggressive/malignant due 624 to the defective senescence barrier, allowing the tumor (precursor) cell to instantly progress to phase III 625 and instigate genomic instability. insights will refine and improve our understanding. Meanwhile, we hope that our model will help foster 637 hypotheses leading to new insights on the molecular life history of glioma, that will help identify 638 convincing therapeutic vulnerabilities.
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